LRRK2-IN-1

• UNSPSC Description:

  LRRK2-IN-1 is a potent and selective?LRRK2?inhibitor with?IC50?of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.

• Target Antigen:

  Apoptosis; LRRK2

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Neurological Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/LRRK2-IN-1.html

• Purity:

  99.42

• Solubility:

  DMSO : 30 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC(OC)=C(NC2=NC=C3C(N(C4=C(C(N3C)=O)C=CC=C4)C)=N2)C=C1)N5CCC(CC5)N6CCN(CC6)C

• Molecular Weight:

  570.69

• References & Citations:

  [1]Hermanson SB, et al. Screening for Novel LRRK2 Inhibitors Using a High-Throughput TR-FRET Cellular Assay for LRRK2 Ser935 Phosphorylation.PLoS One. 2012;7(8):e43580. Epub 2012 Aug 28.|[2]Deng, Xianming., et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature Chemical Biology (2011), 7(4), 203-205.|[3]Koshibu K, et al. Alternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease. Pharmacology. 2015;96(5-6):240-7.|[4]Weygant N, et al. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Mol Cancer. 2014 May 6;13:103.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1234480-84-2